**Core tip:** Stereotactic radiosurgery (SRS) provided an effective long-term local volume control of brain metastases during 12-mo magnetic resonance (MR) imaging follow-up. A significant reduction of the tumor volume by 6 wk post-SRS was associated with long-term volume control suggesting that the timing for MR imaging follow-up at 6 wk, 9 wk, 12 wk and 12 mo after SRS, could be considered the most effective to provide useful information to make the best treatment decisions.

INTRODUCTION
============

Brain metastases account for 20%-40% of adult cancer and affect survival and quality of life\[[@B1]\]. The two most commonly used treatments for brain metastases are whole-brain radiation therapy and stereotactic radiosurgery (SRS), which extend survival from 3 mo to 5 mo and from 7 mo to 13 mo, respectively, depending on tumor type. Surgical resection remains a valuable approach for patients with larger symptomatic metastatic tumors\[[@B2]\].

SRS is an increasingly used procedure for the treatment of primary and metastatic intracranial brain tumors. Indications include patients with few, well-defined, and small intracranial brain tumors. In SRS, radiations are directly delivered into a brain tumor, thus reducing radiation dose of surrounding normal brain tissue and side effects such as neurotoxicity, skin damage, nausea and vomiting\[[@B3]-[@B5]\]. The damage to the peritumoral brain is further reduced by a step dose gradient at the target periphery of the tumor\[[@B3]\].

The objectives of SRS include local tumor control, defined as the absence of a substantial (\< 25%) increase in tumor volume at follow-up magnetic resonance (MR) imaging, improved quality of life, and prolonged survival\[[@B6],[@B8]\]. Metastatic lesions are particularly well-suited for the treatment with SRS because they are usually small (\< 3 cm), well-circumscribed, and have well-defined margins\[[@B6]\].

Studies have demonstrated that SRS is an effective alternative to traditional surgical resection and whole brain radiotherapy in patients with single or few well-defined brain metastases\[[@B1],[@B7]-[@B9]\].

Knowledge of natural history of brain metastases treated with SRS is crucial to prevent management dilemmas, and reduce patient anxiety. For instance, radiation toxicity can sometimes cause a pseudo-progression of brain metastases, which usually resolves with time\[[@B1],[@B7],[@B9],[@B10]\].

The purpose of this study is to evaluate volume tumor control capabilities of SRS in the treatment of brain metastases trough serial MR imaging follow-up.

MATERIALS AND METHODS
=====================

Patient population
------------------

This was a retrospective study approved by the Institutional Review Board of our institution. All patients were referenced with the diagnosis of brain metastases and were treated with Gamma Knife-SRS (Leksell Gamma Knife, model 4C, GammaPlan 5.3; Elekta Instruments, Stockholm, Sweden) at a single academic medical center from January 2015 to January 2016. All patients had given written consent for this retrospective study. Patients were included in this study if they had a pre-treatment MR examination and serial follow-up MR examinations within 6 wk, 9 wk, 12 wk, and 12 mo post-SRS.

Patients were excluded if SRS was performed for consolidation to a surgical resection bed only. Additionally, patients in whom lesions required salvage surgery due to symptomatic local failure, were excluded.

The SRS dose delivered to the tumor margins ranged from 18 to 24 Gy prescribed to the 40%-70% isodose surface. Radioresistant tumors (melanoma, renal cancer) received a median marginal dose of 23.7 Gy (range, 20-24 Gy), and radiosensitive tumors (lung and, breast cancer) received a median marginal dose of 21.3 Gy (range, 18-24 Gy).

There was a total of 31 patients (14 men, 17 women; age: 32-77 years; mean age, 51, 5 years) that underwent serial MR imaging examinations at 6 wk, 9 wk, 12 wk, and 12 mo after SRS.

Brain metastases were confirmed by pathology. There were 54 brain metastases: Non-small cell lung carcinoma *n* = 19 (36%), breast carcinoma *n* = 16 (29%), renal cell carcinoma *n* = 9 (16%), and melanoma *n* = 10 (19%). Patient population and primary cancer types are summarized in Table [1](#T1){ref-type="table"}.

###### 

Patient population and primary cancer types

  **No. of** **patients**   **Gender**        **Age (yr)**   **Primary cancer type**         **No. of lesions, (%)**
  ------------------------- ----------------- -------------- ------------------------------- -------------------------
  11                        7 men - 4 women   50-70          Non-small cell lung carcinoma   19 (36)
  9                         1 men - 8 women   32-60          Breast carcinoma                16 (29)
  7                         5 men - 2 women   55-77          Renal cell carcinoma            9 (16)
  4                         1 men - 3 women   32-65          Melanoma                        10 (19)

MR imaging
----------

All MR examinations were performed with a 1.5T MR scanner (Signa Excite, GE Medical Systems, Milwaukee, United States). MR imaging protocol included axial and sagittal fast spin-echo (FSE) T2W \[5100/110 (TR/TE)\] images, axial fluid-attenuated inversion-recovery (FLAIR) \[8000/140/2400 (TR/TE/TI)\] images, along with axial, sagittal, and coronal non-enhanced and contrast-enhanced (0.1 mmol/Kg gadobutrol - Gadovist, Bayer, Germany) FSE T1W \[650/15 (TR/TE)\] images with a FOV of 22 cm, matrix 512 × 512, slice thickness 5 mm, intersection gap 1 mm, number of excitations 2. Follow-up MR examinations were performed at 6 wk, 9 wk, 12 wk, and 12 mo post-SRS.

Volume change analysis
----------------------

Two experienced neuroradiologists evaluated in consensus the maximum enhancing metastasis volume measured in 3 orthogonal planes at initial MR examinations and at each follow-up. Tumor volume was calculated according to the following formula: Volume = length × width × height/2 as reported in other studies\[[@B7]\]. Metastases of at least 0.5 cm^3^ were included. Metastasis volume change was categorized at each follow-up as increased (\> 20% of the initial volume), stable (± 20% of the initial volume) or decreased (\< 20% of the initial volume). This criteria was chosen taking in account a measurement error of 20%, as there are no validated categorization schemes for tumor response.

Statistical analysis
--------------------

Statistical analysis was performed using the statistical software package SPSS (SPSS, Chicago, Ill). The Wilcoxon signed-rank test for continuous variables was used to evaluate the significance of volume change. A multivariate logistic regression analysis was used to determine the correlation between histopathology and volume changes. A *P* value of \< 0.05 was considered statistically significant.

RESULTS
=======

Primary cancer types and effective time point for MR imaging follow-up to identify significant phases of the response to the SRS therapy are summarized in Table [2](#T2){ref-type="table"}. At 6-wk follow-up, a local tumor control with a significant volume decrease up of 63% was observed in 25 brain metastases (46%) (12 non-small cell lung carcinoma, 11 breast carcinoma, 1 renal cell carcinoma, 1 melanoma). No significant volume change was observed in 23 metastases (43%) (6 non-small cell lung carcinoma, 5 breast carcinoma, 7 renal cell carcinoma, 5 melanoma), and a significant volume increase was observed in 6 metastases (11%) (1 non-small cell lung carcinoma, 1 renal cell carcinoma, 4 melanoma).

###### 

Primary cancer types and effective time point for magnetic resonance imaging follow-up to provide useful information for the treatment decision

  **Primary cancer type**         **No. of lesions**   **%[4](#T2FN4){ref-type="table-fn"}**   **Reduced in size at 6 wk[1](#T2FN1){ref-type="table-fn"}**   **%[4](#T2FN4){ref-type="table-fn"}**   **Pseudo-progression (9 wk)[2](#T2FN2){ref-type="table-fn"}**   **%[4](#T2FN4){ref-type="table-fn"}**   **True-progression (12 mo)[3](#T2FN3){ref-type="table-fn"}**   **%[4](#T2FN4){ref-type="table-fn"}**
  ------------------------------- -------------------- --------------------------------------- ------------------------------------------------------------- --------------------------------------- --------------------------------------------------------------- --------------------------------------- -------------------------------------------------------------- ---------------------------------------
  Non-small cell lung carcinoma   19                   36                                      12                                                            22                                      8                                                               15                                      1                                                              2
  Breast carcinoma                16                   29                                      11                                                            20                                      7                                                               13                                      4                                                              7
  Renal cell carcinoma            9                    16                                      1                                                             2                                       0                                                               0                                       6                                                              11
  Melanoma                        10                   19                                      1                                                             2                                       0                                                               0                                       8                                                              15
  Total                           54                   100                                     25                                                            46                                      15                                                              28                                      19                                                             35

Number of lesions reduced in size at 6-wk follow-up;

Number of lesions that presented a transient volume growth (pseudo-progression) at 9-wk follow-up;

Number of lesions that presented final volume growth (true-progression) at 12-mo follow-up;

Percentage of lesions computed over the total number of lesions (*n* = 54).

At 9-wk follow-up, 15 out of 25 radiosensitive brain metastases (28% of the total lesions) (8 non-small cell lung cancer, 7 breast metastases) that decreased in size at 6 wk had a transient tumor volume increase, followed by tumor regression at 12 wk with no clinical symptoms (pseudo-progression) (Figure [1](#F1){ref-type="fig"}).

![Follow-up axial enhanced T1-weighted magnetic resonance images of a brain metastasis from breast carcinoma treated with stereotactic radiosurgery in a 60-year-old woman. A: Pre stereotactic radiosurgery (SRS) magnetic resonance (MR) image; B: Initial follow-up MR image at 6 wk after SRS demonstrating an initial volume reduction; C: Follow-up MR image at 9 wk after SRS demonstrating a transient volume increase (pseudo-progression); D: Follow-up MR image at 12 wk demonstrating a final volume reduction.](WJR-8-916-g001){#F1}

At 12-wk follow-up, there was a significant reduction in volume in 45 metastases (18 non-small cell lung carcinoma, 14 breast carcinoma, 7 renal cell carcinoma, 6 melanoma), no significant volume change in 5 metastases (1 non-small cell lung carcinoma, 1 breast carcinoma, 1 renal cell carcinoma, 2 melanoma), and a significant volume increase in 4 metastases (1 breast carcinoma, 1 renal cell carcinoma, 2 melanoma).

At 12-mo follow-up, 19 (35%) metastases increased (true-progression) significantly in size (up to 41% of the initial volume) (1 non-small cell lung cancer, 4 breast cancer, 6 renal cell carcinoma, 8 melanoma) (Figure [2](#F2){ref-type="fig"}).

![Follow-up axial enhanced T1-weighted magnetic resonance images of a lung carcinoma metastatic to the right cerebellum treated with stereotactic radiosurgery. A: Pre stereotactic radiosurgery (SRS) magnetic resonance (MR) image; B: Initial follow-up MR image at 6 wk after SRS demonstrating an initial volume reduction; C: Follow-up MR image at 9 wk demonstrating volume increase (true-progression); D: Follow-up MR image at 12 wk with final volume increase.](WJR-8-916-g002){#F2}

The logistic regression analysis showed that volume tumor reduction correlates to histopathologic subtype: non-small cell lung carcinoma had a significant reduction of 38% of its initial volume; breast carcinoma had a significant reduction of 41% of its initial volume; renal cell carcinoma had a significant reduction of 14% of its initial volume; melanoma had a significant reduction of 8% of its initial volume. Thus, higher tumor reduction was observed in the radiation sensitive carcinomas (breast and non-small cell lung carcinomas).

Moreover, we evaluated the volume tumor variation of breast, non-small cell lung cancer, melanoma, and renal cell carcinoma metastases at 6 wk, 9 wk, 12 wk, and 12 mo post-SRS. Our results show that response categorization differences among these 4 primary types were not statistically significant, however melanoma and renal cell carcinoma metastases had less robust volume reduction than non-small cell lung cancer or breast metastases.

Temporary or permanent clinical complications were evaluated during 12 mo follow-up of these patients. Transient headache related to intracranial edema was noted in 10 patients, with nausea (5 patients) and arm or leg weakness (2 patients). Permanent neurologic deficits were noted in 6 patients.

DISCUSSION
==========

Our results suggest that a significant early reduction of tumor volume is associated with a good long-term volume tumor control as reported in previous studies\[[@B6],[@B7],[@B10]-[@B14]\]. Conversely, increased tumor volume at 6-wk follow-up has a higher probability of a final increase in lesion size, thus in a poor tumor volume control.

Transient volume growth at 9-wk follow-up occurred in 15 radiosensitive brain metastases (8 non-small cell lung cancer, 7 breast metastases) (28% of the total lesions), followed by tumor regression at 12 wk with no clinical symptoms (Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}). This transient growth must be careful interpreted as it could be misinterpreted as tumor recurrence, whereas it should be interpreted as a pseudo-progression\[[@B7]\].

The histopathology of pseudo-progression is probably related to treatment-induced tumor inflammation and necrosis\[[@B7],[@B10]-[@B13]\]. Tumor volume variation trend in our series demonstrates that melanoma and renal cell carcinoma metastases showed less volume reduction than non-small cell lung cancer or breast metastases.

However, response categorization differences among these 4 primary types were not statistically significant, thus suggesting that the most effective timing for MR imaging follow-up, regardless the type of primary tumor, could be considered at 6 wk, 9 wk, 12 wk and 12 mo after SRS.

The observation that a small percentage of lesions may undergo a transient volume increase indicate that initial lesion growth does not necessary preclude local volume control. Conversely, there were a low number of metastases that exhibited initial volume growth and continued to grow with no volume control during SRS (Figure [2](#F2){ref-type="fig"}).

SRS has become the standard procedure for the treatment of brain metastases as it allows a longer survival and higher local control rates compared to whole-brain radiation therapy\[[@B6],[@B7],[@B9],[@B14]\]. Compared to surgical resection, SRS is associated to lower morbidity and decrease cost\[[@B1]\].

To summarize, SRS is effective in treating brain metastases regardless of their histology, including those that are radio-resistant to conventional whole-brain radiation therapy, such as metastases that originates from melanoma and renal cell carcinoma.

Although initial consistent tumor volume reduction after SRS is predictive of long term volume control, initial tumor growth does not necessarily indicate tumor progression but radiation-induced inflammation and necrosis (pseudo-progression) and it should be taken into account to avoid to be misinterpreted as a recurrence.

Limitations
-----------

This study was a retrospective, single-institution study with a relative small size population and these factors could be considered limitations.

To prevent potential inaccuracies in the volume measurement of the intracranial lesion, we excluded lesions with an initial tumor volume of less than 0.5 cm^3^ and a 20% cutoff for volume response categorization was chosen.

In conclusion, effective long-term SRS local volume control of brain metastases can be demonstrated at 12 mo follow-up. Significant tumor volume reduction by 6 wk post-SRS was associated with long-term volume control suggesting that the timing for MR imaging follow-up at 6 wk, 9 wk, 12 wk and 12 mo after SRS, could be considered the most effective to provide useful information to make the best treatment decisions. Although it is necessary to validate these results in a larger, prospective series, the results are encouraging that an early local volume reduction after SRS is associated with significant local control for metastatic brain lesions.

COMMENTS
========

Background
----------

Brain metastases account for 20% to 40% of adult cancer and affect both survival and quality of life. Brain metastases volume reduction is associated with significant local control of the lesions and prolongation of patient's survival. Stereotactic radiosurgery (SRS) is an increasingly used procedure for the treatment of primary and metastatic intracranial brain tumors to achieve local volume reduction.

Research frontiers
------------------

Volume tumor control capabilities of SRS in the treatment of brain metastases is an important factor for post-treatment decision making and delivery salvage therapy.

Innovations and breakthroughs
-----------------------------

Volume tumor control capabilities of SRS could be demonstrated trough serial magnetic resonance (MR) imaging follow-up. Accurate determination of the timing for MR imaging follow-up is crucial for decision making and delivery timely salvage therapy.

Applications
------------

Serial MR imaging follow-up at 6 wk, 9 wk, 12 wk, and 12 mo is the most effective timing to demonstrate volume reduction of brain metastases after SRS. The information derived from serial MR imaging follow-up could affect clinical management and improve survival of these patients.

Terminology
-----------

SRS is a procedure for the treatment of primary and metastatic intracranial brain tumors. Indications include patients with few, well-defined, and small intracranial brain tumors. In SRS, radiations are directly delivered into a brain tumor, thus reducing radiation dose of surrounding normal brain tissue and side effects such as neurotoxicity, skin damage, nausea and vomiting. The damage to the peritumoral brain is further reduced by a step dose gradient at the target periphery of the tumor. The objectives of SRS include local tumor control, defined as the absence of a substantial (\< 25%) increase in tumor volume at follow-up MR imaging, improved quality of life, and prolonged survival.

Peer-review
-----------

This study is interesting. However the manuscript would be of higher value to the reader if the manuscript focuses on the pseudo-progression period, that period is confusing for the practicing physician and can lead to misinterpretation and additional or changes in treatment strategies.
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